BioInfra KRX:199730KOSDAQ
바이오인프라 · Korean news coverage and regulatory filings, organized.
Articles, 24h0
Articles, 7 days0
DART filings, 7 days0
Articles tracked6since Sep 11
In Q2 2026, BioInfra reported revenue of ₩8.5bn, up 39.7% year on year, and operating profit of ₩76m. BioInfra (바이오인프라) appeared in 0 Korean news articles and 0 DART filings over the past seven days.
Filing signals Turnaround High dividend Insider buying M&A / stake deal Dividend cut Delisting / halt risk Screener
BioInfra quarterly results separate, KRW
| Quarter | Revenue | YoY | Operating profit | Net income |
|---|---|---|---|---|
| Q2 2026 | ₩8.5bn | +39.7% | ₩76m margin 0.9% | ₩2m |
| Q1 2026 | ₩5.5bn | +1.1% | −₩2.4bn margin −43.8% | −₩2.5bn |
| Q3 2025 | ₩5.1bn | -33.5% | −₩2.1bn margin −40.5% | −₩2.2bn |
| Q2 2025 | ₩6.1bn | +3.8% | −₩1.1bn margin −18.4% | −₩1.6bn |
| Q1 2025 | ₩5.4bn | +8.3% | −₩2.2bn margin −40.6% | −₩1.7bn |
| Q3 2024 | ₩7.6bn | – | −₩1.1bn margin −15.1% | −₩1.2bn |
| Q2 2024 | ₩5.9bn | – | −₩1.3bn margin −22.3% | −₩1.2bn |
| Q1 2024 | ₩5.0bn | – | −₩1.5bn margin −30.0% | −₩1.5bn |
Key accounts from quarterly, half-year and annual reports filed on DART. Q4 is derived as full-year minus nine-month figures. Figures may differ from preliminary earnings releases. Margin is operating profit divided by revenue — see operating margin.
BioInfra top stories 2 weeks, by number of outlets
No story covered by multiple outlets in the past two weeks.